Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PV-10 in NET metastatic to the liver
NCT02693067Phase 1Unknown
- Sponsor
- Provectus Biopharmaceuticals
- Start
- Jul 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rose bengal in neuroendocrine tumors (NETs), sponsored by Provectus Biopharmaceuticals. Primary endpoint: Number of Participants with Adverse Events at 28 days. Status: unknown.
02
Drugs
rose bengal
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT02693067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693067.